<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941028-2-00070</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Written comments by February 15, 1995. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 92D&hyph;0296]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Guidance Manual for Computer Assisted New Drug Applications; Availability <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is announcing the availability of the revised guidance manual entitled ``Computer Assisted New Drug Application (CANDA) Guidance Manual.'' This manual was developed by FDA's Center for Drug Evaluation and Research (CDER), in conjunction with the pharmaceutical industry. The manual provides guidance for the submission of computer assisted new drug applications (CANDA's), investigational new drug applications (IND's), and abbreviated new drug applications (ANDA's).  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Written comments by February 15, 1995. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit written requests for single copies of the guidance manual to the CDER Executive Secretariat Staff (HFD&hyph;8), Center for Drug Evaluation and Research, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send two self-addressed adhesive labels to assist that office in processing your request. Submit written comments on the guidance manual to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;24, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. A copy of the guidance manual and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Instructions for obtaining the guidance manual electronically can be found in the ``Supplementary Information'' section of this document. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> David M. Moss, Center for Drug Evaluation and Research (HFD&hyph;70), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;2836. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) requires drug sponsors to submit new drug applications (NDA's) to FDA for review and approval before marketing in the United States. FDA's review processes culminate in a risk-benefit assessment and regulatory decision. To arrive at a substantive risk-benefit assessment and confident regulatory decision, the agency must evaluate all information and data provided via the application supporting safety, efficacy, and/or other claims.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The agency has been assessing the use of automation technology to support and assist in premarketing review processes and has found that technology holds the potential for enhancing review process quality and efficiencies. Consequently, the agency supports the use of electronic submissions by the pharmaceutical industry. <!-- PJG 0012 frnewline --> In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of October 9, 1992 (57 FR 46565), FDA published a notice announcing that the draft guidance manual for CANDA's was available in hard copy and electronically. The guidance manual provides general guidance to assist the pharmaceutical industry in preparing and submitting CANDA's that are effective and capable of being evaluated. In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of April 8, 1993 (59 FR 18218), the agency published a notice announcing the procedures for revising the draft guidance manual, and that the revised guidance manual would be available electronically. <!-- PJG 0012 frnewline --> Please note that an accompanying paper submission of the application remains a requirement at this time. The electronic version should correspond exactly to the paper version; where it does not, the differences are to be specified. Currently, assessment of electronic submissions versus paper submissions is underway.  <!-- PJG 0012 frnewline --> The ``CANDA Guidance Manual'' discusses procedures of general applicability that are acceptable to the agency, but are not legal requirements. The ``CANDA Guidance Manual'' does not bind the agency, nor does it create or confer any rights, privileges, benefits, or obligations for or on any person. <!-- PJG 0012 frnewline --> The agency will distribute copies free of charge since the electronic submission program is evolving and the manual provides recommended interim guidance and procedures, and does not mandate electronic submission specifications. <!-- PJG 0012 frnewline --> An electronic version of the guidance manual is available via Internet. Requestors should connect to the CDER FTP server using the FTP protocol. The manual and updates are available in the sub-directory ``CANDA'' in both WordPerfect Version 5.2 and an ASCII version. Individual chapters are also available. The file READ.ME in the CANDA sub-directory lists the file names of the WordPerfect and ASCII versions of the entire document and each chapter. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 2,L2,i1,s100,r100 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Sample for the CANDA Guidance Manual <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Sample for Updates To the CANDA Guidance Manual <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=01 g=1 f=1 --> FTP CDV2.CDER.FDA.GOV <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> FTP CDV2.CDER.FDA.GOV <!-- PJG 0012 frnewline --> LOGIN ANONYMOUS <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> LOGIN ANONYMOUS <!-- PJG 0012 frnewline --> &lt;ANY PASSWORD> <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &lt;ANY PASSWORD> <!-- PJG 0012 frnewline --> BINARY <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> CD CANDA  <!-- PJG 0012 frnewline --> CD CANDA  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> GET CANDA.UPDATE <!-- PJG 0012 frnewline --> GET CANDA.WPC  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> &blank; <!-- PJG 0012 frnewline --> EXIT <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> EXIT <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Interested persons may, on or before February 15, 1995, submit written comments on the guidance manual to the Dockets Management Branch (address above). FDA will consider these comments in determining whether further revisions to the draft guidance manual are warranted. Two copies of any comments should be submitted, except that individuals may submit one copy. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: October 24, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> William K. Hubbard, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Interim Deputy Commissioner for Policy. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;26729 Filed 10&hyph;27&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            